Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer - Trial NCT06118762
Access comprehensive clinical trial information for NCT06118762 through Pure Global AI's free database. This Phase 4 trial is sponsored by The First Affiliated Hospital of Nanchang University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The First Affiliated Hospital of Nanchang University
Timeline & Enrollment
Phase 4
Oct 20, 2023
Oct 01, 2026
Primary Outcome
Progression free survival (PFS)
Summary
To evaluate the efficacy and safety of Fruquintinib combined with Raltitrexed in the
 treatment of metastatic colorectal cancer that progressed or could not be tolerated after
 previous fluorouracil, oxaliplatin, and irinotecan based therapy
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06118762
Non-Device Trial